Intact Investment Management Inc. Purchases Shares of 3,000 Illumina, Inc. (NASDAQ:ILMN)

Intact Investment Management Inc. purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 3,000 shares of the life sciences company’s stock, valued at approximately $418,000.

Several other large investors have also added to or reduced their stakes in the company. Eukles Asset Management lifted its holdings in Illumina by 1.7% during the third quarter. Eukles Asset Management now owns 5,942 shares of the life sciences company’s stock valued at $816,000 after purchasing an additional 100 shares in the last quarter. Clear Creek Financial Management LLC lifted its holdings in Illumina by 6.3% during the fourth quarter. Clear Creek Financial Management LLC now owns 1,695 shares of the life sciences company’s stock valued at $236,000 after purchasing an additional 100 shares in the last quarter. Lido Advisors LLC lifted its holdings in Illumina by 6.1% during the third quarter. Lido Advisors LLC now owns 1,859 shares of the life sciences company’s stock valued at $255,000 after purchasing an additional 107 shares in the last quarter. Quent Capital LLC lifted its holdings in shares of Illumina by 45.2% in the fourth quarter. Quent Capital LLC now owns 363 shares of the life sciences company’s stock worth $51,000 after buying an additional 113 shares in the last quarter. Finally, Independent Advisor Alliance lifted its holdings in shares of Illumina by 8.6% in the third quarter. Independent Advisor Alliance now owns 1,595 shares of the life sciences company’s stock worth $219,000 after buying an additional 126 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, CEO Jacob Thaysen purchased 7,330 shares of Illumina stock in a transaction on Thursday, February 22nd. The stock was bought at an average price of $135.29 per share, for a total transaction of $991,675.70. Following the transaction, the chief executive officer now owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.17% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several research analyst reports. Barclays boosted their target price on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a report on Wednesday, April 10th. Stephens reissued an “overweight” rating and issued a $170.00 target price on shares of Illumina in a report on Wednesday, April 10th. StockNews.com raised shares of Illumina from a “hold” rating to a “buy” rating in a report on Friday, February 16th. OTR Global reaffirmed a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Finally, TD Cowen downgraded shares of Illumina from an “outperform” rating to a “market perform” rating and set a $144.00 target price on the stock. in a research note on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, Illumina has a consensus rating of “Hold” and an average target price of $167.70.

Illumina Price Performance

NASDAQ ILMN opened at $122.28 on Monday. Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $213.91. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.26. The business’s 50-day simple moving average is $131.51 and its 200-day simple moving average is $127.24.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, February 8th. The life sciences company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the company posted $0.14 EPS. Illumina’s revenue for the quarter was up 3.6% on a year-over-year basis. On average, research analysts anticipate that Illumina, Inc. will post 0.91 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.